Seizure Treatment in Children Transported to Tertiary Care: Recommendation Adherence and Outcomes

Heather M Siefkes1,2, Maija Holsti3, Denise Morita4

  • 1Divisions of Critical Care Medicine and hsiefkes@ucdavis.edu.

Pediatrics
|December 13, 2016
PubMed

Insights

Poor adherence to recommended pediatric seizure treatment in emergency departments increases intubation risk. Improving care for children with seizures is crucial for better outcomes.

Area of Science:

  • Pediatric Emergency Medicine
  • Neurology
  • Clinical Quality Improvement

Background:

  • Convulsive seizures represent a significant reason for pediatric air transport, accounting for 15% of cases.
  • Evaluating the quality of acute seizure management in emergency departments is essential for optimizing patient care.

Purpose of the Study:

  • To assess adherence to recommended management protocols for acute seizure treatment in pediatric patients undergoing air transport.
  • To determine the impact of adherence on patient outcomes, specifically intubation rates.

Main Methods:

  • A retrospective cohort study analyzed data from children transported for acute seizures to a tertiary pediatric hospital between 2010 and 2013.
  • Seizure treatment was retrospectively evaluated for adherence to established guidelines.
  • The primary outcome measure was the need for intubation.

Main Results:

  • 61% of seizure events did not receive recommended acute treatment, with over-administration of benzodiazepines being a common deviation.
  • Non-adherence to recommended care significantly increased the risk of intubation (RR 2.4) and intensive care unit (ICU) admission (RR 1.65).
  • Weight-based benzodiazepine dosing was suboptimal in 68% of cases, with underdosing being prevalent.

Conclusions:

  • Adherence to evidence-based acute seizure treatment in community emergency departments for pediatric patients is suboptimal.
  • Failure to provide recommended care is associated with higher rates of intubation.
  • Targeted educational interventions and quality improvement initiatives are needed to enhance pediatric seizure management in emergency settings.
Abstract

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.6K
Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
1.9K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.1K
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
880
Electroconvulsive Therapy01:30

Electroconvulsive Therapy

Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
1.7K
Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
2.1K